ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

RLMD vs CAPR // OPTIONS IMPLIED MOVE & PUT/CALL SKEW

Relmada Therapeutics Inc. (NASDAQ) VS. Capricor Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: RLMD 2 — CAPR 2
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (RLMD VS. CAPR) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC RLMD CAPR SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -35.00% 0.00 TIE /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield -12.48% -18.86% +6.38 RLMD /fcf-yield <GO>
Operating Margin — — — TIE /operating-margins <GO>
Net Profit Margin — — — TIE /net-margins <GO>
Revenue Growth (YoY) — — — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — 3.38 — TIE /balance-sheet <GO>
Piotroski F-Score Quality 1/9 2/9 -1.00 CAPR /piotroski-score <GO>
Options Implied Move & Put/Call Skew ACTIVE — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 52.9 41.6 +11.30 RLMD /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $366.9M $385.5M -$18.5M CAPR /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR RLMD REV CAPR REV RLMD GROSS % CAPR GROSS % RLMD FCF CAPR FCF
FY 2025 $0 $0 — — -$45.8M -$72.7M
FY 2024 $0 $22.3M — — -$51.8M -$41.2M
FY 2023 — $25.2M — — — -$25.6M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
RLMD // BETA —
CAPR // BETA —